Oxford's Covid-19 vaccine India trial: Serum Institute asked to modify protocol

It’s Not Just Anti Vaxxers Who Worry About Vaccines

All of us are expecting a vaccine within this year to put an end to the ongoing pandemic. According to J&J, this immune response successfully prevented subsequent infection and provided complete or near-complete protection from the SARS-CoV-2 virus, which causes COVID-19.

The study saw the monkeys given a panel of vaccine prototypes before being exposed to SARS-CoV-2 infection. Barouch's group, in collaboration with Johnson & Johnson, developed a series of vaccine candidates created to express different variants of the SARS-CoV-2 spike protein, which is the major target for neutralizing antibodies. They have created a series of vaccine candidates designed to express different variants of the virus spike protein.

What distinguishes J&J's trial is that its vaccine showed strong protection in a single dose. Then the remaining 20 animals received placebo shots. All vaccinated animals developed neutralizing antibodies following immunization. The animals that received placebo shots showed a high level of damage in their lungs.

The best performing candidate that was chosen by J&J for human trials showed that no animal had a virus in their lungs, and the lower level of the virus was demonstrated by only one in the nasal swab. The results of the study reported in the journal Nature.

Initial results of the first two-phase trials of the vaccine conducted in five trial sites in the United Kingdom showed it has an acceptable safety profile and homologous boosting increased antibody responses, the source said.

Of the seven variations, Ad26.COV2.S provides the most effective immune response, which will help humans to protect against COVID-19. In some places, the human trial of Corona's vaccines began in April. Kathryn E. Stephenson, assistant professor of medicine at HMS and associate member of the Ragon Institute, is the principal investigator for the trial at BIDMC, which is funded by Janssen Vaccines & Prevention.

The Subject Expert Committee at Central Drugs Standard Control Organisation (CDSCO) has recommended to the top drug regulator to grant permission to Serum Institute of India (SII) to conduct phase two and three clinical trials in India on a potential COVID-19 vaccine, a Health Ministry official said on Friday.

Related:

Comments


Other news